Advanced search


Search results        Search results      Copy URL to E-Mail


Development of an abdominal myofascial release therapy intervention for children with irritable bowel syndrome: Feasibility, acceptability, and preliminary outcomes

Journal: Neurogastroenterology and Motility Date: 2024/11, 36(S1):Pages: PP174. doi: Subito , type of study: pretest posttest design

Full text    (https://onlinelibrary.wiley.com/doi/10.1111/nmo.14902)

Keywords:

children [301]
conference abstract [121]
IBS [33]
irritable bowel syndrome [41]
MFR [9]
myofascial release [56]
pediatrics [535]
pretest posttest design [217]
quality of life [110]

Abstract:

Objectives: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain, bloating, and altered defecation patterns significantly impacting quality of life (QoL). Treatments can differ depending on the subtype; however, therapies often do not completely relieve symptoms. Myofascial release (MFR) is a gentle hands-on technique targeting the fascia. MFR techniques applied during osteopathic manipulations have resulted in improvement of abdominal pain, distention, constipation, and QoL in adults. Therefore, we sought to evaluate the feasibility, acceptability, and effect on symptoms and QoL of an abdominal wall targeted MFR intervention in children with IBS. Methods: Children meeting Rome IV criteria for IBS were enrolled and received six one-h abdominal MFR sessions during six weeks by a certified MFR massage therapist and were educated on administering self-MFR at home using a rubber ball. Validated pediatric questionnaires, the PedsQL™ Gastrointestinal Symptoms Module and the Pediatric Quality of Life Inventory™ were administered at baseline, end of intervention, and one month post intervention. All outcomes were analyzed using Mixed Model for Repeated Measures method. Results: Sixteen children with IBS were enrolled. Of these, 14 children (median age 16 years, 50% female), completed 6 MFR sessions and questionnaires. Fascia restrictions were identified and released in all participants. Self-MFR practice averaged three times per week and 7 min per day. Total GI symptom scores significantly improved at end of intervention (p = 0.005) and one month post intervention (p = 0.0005). QoL total scores significantly improved at end of intervention (p = 0.02). Similarly, caregiver reported total GI symptom and QoL scores significantly improved at both timepoints (p < 0.05). No adverse events were reported. Conclusions: Abdominal MFR therapy is feasible to administer and is well-tolerated in children with IBS. Preliminary results show that six weeks of abdominal MFR improves overall IBS-associated symptoms and QoL up to one month following the intervention. Randomized controlled trials are needed to further evaluate the efficacy of abdominal MFR in IBS and variability between IBS subtypes that would support implementation as a non-invasive therapy for children with IBS.


Search results      Copy URL to E-Mail

 
 
 






  • ImpressumLegal noticeDatenschutz


ostlib.de/data_envhmgwjqsxcpadfkruy



Supported by

OSTLIB recommends